- Home
- PVLA vs PGEN Comparison
PVLA vs PGEN Comparison
Compare PVLA & PGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PVLA | PGEN |
|---|---|---|
| Founded | 2015 | 1998 |
| Country | United States | United States |
| Employees | 14 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.4B |
| IPO Year | N/A | 2013 |
Fundamental Metrics
Financial Performance| Metric | PVLA | PGEN |
|---|---|---|
| Price | $127.43 | $4.38 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 15 | 5 |
| Target Price | ★ $171.87 | $8.33 |
| AVG Volume (30 Days) | 160.9K | ★ 2.7M |
| Earning Date | 05-12-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $230,981,000.00 |
| Revenue This Year | N/A | $1,115.92 |
| Revenue Next Year | $104,350.18 | $81.04 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $20.20 | $1.23 |
| 52 Week High | $151.18 | $5.47 |
Technical Indicators
Market Signals| Indicator | PVLA | PGEN |
|---|---|---|
| Relative Strength Index (RSI) | 55.58 | 62.66 |
| Support Level | $108.99 | $3.97 |
| Resistance Level | $135.23 | $4.40 |
| Average True Range (ATR) | 6.85 | 0.21 |
| MACD | -0.17 | 0.02 |
| Stochastic Oscillator | 59.42 | 97.34 |
Price Performance
Historical ComparisonAbout PVLA Palvella Therapeutics Inc.
Palvella Therapeutics Inc is a late clinical-stage biopharmaceutical company committed to serving individuals suffering from serious, rare genetic skin diseases without approved therapies. The Company's lead product candidate, QTORIN 3.9 percent rapamycin anhydrous gel (QTORIN rapamycin), is based on the Company's patented QTORIN platform. QTORIN rapamycin is in clinical development for two rare genetic skin disorders.
About PGEN Precigen Inc.
Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.